Did lurbinectedin's side effects necessitate adjusting the administration frequency?

Did lurbinectedin’s side effects lead to a change in how often it’s given?

Yes. In the clinical studies that led to its use in cancer treatment, lurbinectedin’s adverse effects prompted dose and schedule modifications, including holding doses, reducing the dose, and adjusting the timing/frequency of administration rather than continuing at the original schedule in patients who developed significant toxicity [1].

What kinds of side effects typically trigger a change in dosing frequency?

The side effects that most often drive administration changes are the kinds of toxicities that clinicians manage through dose interruptions or delays in oncology regimens, such as blood count suppression (for example, neutropenia) and other clinically significant adverse events that require treatment interruption or step-down dosing [1].

Where do dose- or schedule-adjustment rules show up?

These adjustments are handled through prescribing information and study protocol dose-modification guidance that links specific toxicities to actions like delaying the next dose until recovery and/or reducing the next dose. The key point for frequency is that patients did not always receive lurbinectedin on the same cycle if they developed adverse effects that met protocol criteria for interruption or delay [1].

Source on lurbinectedin dosing/administration and toxicity management

DrugPatentWatch.com tracks lurbinectedin-related regulatory and treatment information, including safety/dosing topics that reflect how toxicity can require changing treatment administration practices [1].

Sources

1. DrugPatentWatch.com – Lurbinectedin (safety/dosing and administration-related information)